First-Line Treatment for Menorrhagia

When it comes to treating menorrhagia, the levonorgestrel-releasing intrauterine system (LNG-IUS) is considered the first-line option by NICE. This is especially true for women with no identified pathology, fibroids less than 3 cm in diameter, or suspected or diagnosed adenomyosis. While the combined oral contraceptive pill is also an option, it is not the preferred choice.

It is important to note that a repeat ultrasound may not be the next step in management, as the history of menorrhagia is the crucial point to consider. If menorrhagia is not present, the treatment plan may differ. Ulipristal acetate may be used for larger fibroids, but it is typically started in secondary care. Referral for surgical treatment should not be the first-line option, as more conservative measures should be tried initially.

If a patient experiences reddening and thickening of the nipple and areola, it is important to consider the possibility of Paget’s disease of the breast. However, it is also possible that the symptoms are caused by nipple eczema, especially if the patient has a history of atopy and no personal or family history of breast disease. It is important to rule out Paget’s disease, as it typically presents unilaterally and may be accompanied by bloody nipple discharge and an underlying breast lump.

Understanding Paget’s Disease of the Nipple

Paget’s disease of the nipple is a condition that affects the nipple and is associated with an underlying breast cancer. It is present in only 1-2% of patients with breast cancer, but it is important to note that half of these patients have an underlying mass lesion, and 90% of them will have an invasive carcinoma. Even patients without a mass lesion may still have an underlying carcinoma, which is found in 30% of cases. The remaining patients will have carcinoma in situ.

Unlike eczema of the nipple, Paget’s disease primarily affects the nipple and later spreads to the areolar. Diagnosis is made through a combination of punch biopsy, mammography, and ultrasound of the breast. Treatment options will depend on the underlying lesion.

Compared to the Mirena IUS, the Kyleena IUS has a lower rate of amenorrhoea. The Kyleena IUS is a newly licensed contraceptive that contains 19.5mg of levonorgestrel and can be used for up to 5 years. However, it is not licensed for managing heavy menstrual bleeding or providing endometrial protection as part of hormonal replacement therapy, unlike the Mirena IUS. The Kyleena IUS is smaller in size than the Mirena coil, and the Jaydess IUS contains the least amount of LNG at 13.5mg but is only licensed for 3 years. While the lower LNG in the Kyleena IUS may result in a higher number of bleeding/spotting days, overall, the number of such days is likely to be lower than other doses of LNG-IUS. Women may prefer the Kyleena IUS over the Mirena IUS due to its lower systemic levonorgestrel levels.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

Endometriosis: A Possible Cause of Chronic Pelvic Pain

Endometriosis is a condition that can cause chronic pelvic pain, period-related pains, gastrointestinal symptoms, urinary symptoms, deep dyspareunia, and subfertility in female patients. Although a normal ultrasound scan is possible in endometriosis, a diagnostic laparoscopy may be required to make the diagnosis. It is important to consider endometriosis in a patient presenting with these symptoms, even in the absence of period-related symptoms. Other possible causes may not explain the period-related urinary symptoms, making endometriosis a likely culprit. Proper diagnosis and treatment can help alleviate the symptoms and improve the patient’s quality of life.

Breast cancers can be detected by the presence of the tumour marker CA 15-3.

Understanding Tumour Markers

Tumour markers are substances that can be found in the blood, urine, or tissues of people with cancer. They are used to help diagnose and monitor cancer, as well as to determine the effectiveness of treatment. Tumour markers can be divided into different categories, including monoclonal antibodies against carbohydrate or glycoprotein tumour antigens, tumour antigens, enzymes, and hormones. However, it is important to note that tumour markers usually have a low specificity, meaning that they can also be present in people without cancer.

Monoclonal antibodies are a type of tumour marker that target specific carbohydrate or glycoprotein tumour antigens. Some examples of monoclonal antibodies and their associated cancers include CA 125 for ovarian cancer, CA 19-9 for pancreatic cancer, and CA 15-3 for breast cancer.

Tumour antigens are another type of tumour marker that are produced by cancer cells. Examples of tumour antigens and their associated cancers include prostate specific antigen (PSA) for prostatic carcinoma, alpha-feto protein (AFP) for hepatocellular carcinoma and teratoma, carcinoembryonic antigen (CEA) for colorectal cancer, S-100 for melanoma and schwannomas, and bombesin for small cell lung carcinoma, gastric cancer, and neuroblastoma.

Understanding tumour markers and their associations with different types of cancer can aid in the diagnosis and management of cancer. However, it is important to interpret tumour marker results in conjunction with other diagnostic tests and clinical findings.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

Prior to initiating tamoxifen treatment, women should be informed about the elevated risk of VTE, which is one of the most significant side effects of the medication. Additionally, tamoxifen has been linked to an increased risk of endometrial cancer.

Risk Factors for Venous Thromboembolism

Venous thromboembolism (VTE) is a condition where blood clots form in the veins, which can lead to serious complications such as pulmonary embolism (PE). While some common predisposing factors include malignancy, pregnancy, and the period following an operation, there are many other factors that can increase the risk of VTE. These include underlying conditions such as heart failure, thrombophilia, and nephrotic syndrome, as well as medication use such as the combined oral contraceptive pill and antipsychotics. It is important to note that around 40% of patients diagnosed with a PE have no major risk factors. Therefore, it is crucial to be aware of all potential risk factors and take appropriate measures to prevent VTE.

The diagnosis of vaginal candidiasis doesn’t necessarily require a high vaginal swab if the symptoms are highly indicative of the condition. According to NICE guidelines, if a patient presents with classic symptoms such as thick-white discharge, dysuria, itching, and dyspareunia, objective testing is not necessary to confirm the diagnosis. Therefore, the patient can be prescribed oral fluconazole without the need for a swab.

It is incorrect to assume that a healthcare professional or self-collected high vaginal swab is necessary for diagnosis. As mentioned earlier, the patient’s symptoms are highly suggestive of candidiasis, making a swab unnecessary.

Similarly, a mid-stream urine sample for sensitivities is not appropriate in this case. This type of test would be more suitable if the patient had symptoms indicative of a urinary tract infection. However, since the patient denies urinary urgency and frequency, a UTI is unlikely. The change in discharge consistency, which is characteristic of vaginal candidiasis, further supports this diagnosis. Therefore, a urine sample is not required.

Vaginal candidiasis, commonly known as ‘thrush’, is a prevalent condition that many women self-diagnose and treat. Candida albicans is responsible for 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain conditions such as diabetes mellitus, drug use (antibiotics, steroids), pregnancy, and immunosuppression (HIV) may increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, dyspareunia, dysuria, itching, vulval erythema, fissuring, and satellite lesions.

Routine high vaginal swabs are not necessary if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy. The NICE Clinical Knowledge Summaries recommends oral fluconazole 150 mg as a single dose as the first-line treatment. If oral therapy is contraindicated, a single dose of clotrimazole 500 mg intravaginal pessary may be used. If vulval symptoms are present, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments such as cream or pessaries, as oral treatments are not recommended.

Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and the diagnosis of candidiasis should be confirmed. A high vaginal swab for microscopy and culture may be necessary, and a blood glucose test should be performed to exclude diabetes. Differential diagnoses such as lichen sclerosus should also be ruled out. An induction-maintenance regime may be used, consisting of oral fluconazole every three days for three doses as induction, followed by oral fluconazole weekly for six months as maintenance.

Topical Oestrogens for Genitourinary Symptoms of Menopause

Topical oestrogens can be used alongside transdermal/oral HRT to treat genitourinary symptoms of menopause. In fact, systemic HRT doesn’t improve these symptoms in 10-15% of women. Topical oestrogens are effective in these cases and can be combined with systemic HRT.

Combined HRT is not better than oestrogen-only therapy for treating genitourinary symptoms, and progestogens are only used for endometrial protection. If a patient already has protection via an IUS, combination therapy would not be beneficial. Topical oestrogen preparations have been shown to improve vaginal symptoms, including vaginal atrophy and pH decrease, and to increase epithelial maturation compared to placebo or non-hormonal gels.

It is important to note that systemic absorption of vaginal oestrogen is very low. Therefore, topical oestrogens work better for genitourinary symptoms of menopause compared to oral HRT and can be used in combination. According to NICE NG23, vaginal oestrogen should be offered to women with urogenital atrophy, including those on systemic HRT, and treatment should continue for as long as needed to relieve symptoms.

If vaginal oestrogen doesn’t relieve symptoms, the dose can be increased after seeking advice from a healthcare professional with expertise in menopause. Women should be informed that symptoms often return when treatment is stopped, but adverse effects from vaginal oestrogen are very rare. They should report any unscheduled vaginal bleeding to their GP. Additionally, moisturisers and lubricants can be used alone or in addition to vaginal oestrogen for vaginal dryness. Routine monitoring of endometrial thickness during treatment for urogenital atrophy is not necessary.

Chlamydia is best diagnosed using nucleic acid amplification tests (NAATs), which are highly sensitive and specific. In clinical practice, NAATs are the preferred method of testing. For females, vulvo-vaginal swabs are the most effective, while urethral swabs are typically used for men. Although cultures are also highly sensitive and specific, they can be less effective due to various factors such as inadequate specimen collection and overgrowth of cell cultures. Additionally, cell culture is expensive and requires experienced technicians. Patients who test positive for chlamydia should also be advised on the risks associated with unprotected sex and offered long-acting contraceptives. A pregnancy test may also be necessary.

Chlamydia is the most common sexually transmitted infection in the UK caused by Chlamydia trachomatis. It is often asymptomatic but can cause cervicitis and dysuria in women and urethral discharge and dysuria in men. Complications include epididymitis, pelvic inflammatory disease, and infertility. Testing is done through nuclear acid amplification tests (NAATs) on urine or swab samples. Screening is recommended for sexually active individuals aged 15-24 years. Doxycycline is the first-line treatment, but azithromycin may be used if contraindicated. Partners should be notified and treated.

For women who are at high risk of STIs, have recently undergone a gynaecological or obstetric procedure (including delivery), or are pregnant, it is recommended to undergo an examination. In cases of new-onset vaginal discharge, an intimate examination is advised. If the patient has had an intrauterine system inserted recently and is experiencing a recurrence of bacterial vaginosis, an examination should be conducted before determining the next course of action.

Understanding Vaginal Discharge: Common and Less Common Causes

Vaginal discharge is a common symptom experienced by many women, but it is not always a sign of a serious health issue. In fact, some amount of discharge is normal and helps to keep the vagina clean and healthy. However, when the discharge is accompanied by other symptoms such as itching, burning, or a foul odor, it may be a sign of an underlying condition.

The most common causes of vaginal discharge include Candida, Trichomonas vaginalis, and bacterial vaginosis. Candida is a fungal infection that can cause a thick, white discharge that resembles cottage cheese. Trichomonas vaginalis is a sexually transmitted infection that can cause a yellow or green, frothy discharge with a strong odor. Bacterial vaginosis is a bacterial infection that can cause a thin, gray or white discharge with a fishy odor.

Less common causes of vaginal discharge include gonorrhea, chlamydia, ectropion, foreign bodies, and cervical cancer.

According to NICE, the treatment of premenstrual syndrome should be approached from various angles, taking into account the severity of symptoms and the patient’s preferences. Effective treatment options include non-steroidal anti-inflammatory drugs taken orally, combined oral contraceptive, cognitive behavioural therapy and selective serotonin reuptake inhibitors. However, the copper intrauterine device, tricyclic antidepressants, diazepam and progestogen only pill are not recommended as treatment options.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and doesn’t occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this condition.

To minimize the risk of breast cancer, it is recommended to avoid adding progestogen in hormone replacement therapy (HRT). Therefore, women who have had a hysterectomy are usually prescribed oestrogen-only treatment. According to the British National Formulary (BNF), the risk of stroke remains unchanged regardless of whether the HRT preparation includes progesterone.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

If a woman is 55 years or older and experiences postmenopausal bleeding (i.e. bleeding occurring more than 12 months after her last menstrual cycle), she should be referred through the suspected cancer pathway within 2 weeks to rule out endometrial cancer. As this woman is over 50 years old and has not had a menstrual cycle for over a year, she has reached menopause and doesn’t require blood tests to confirm it. The recent vaginal bleeding she has experienced is considered postmenopausal bleeding and requires further investigation to eliminate the possibility of endometrial cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Symptoms of endometrial cancer include postmenopausal bleeding, which is usually slight and intermittent at first before becoming heavier, and changes in intermenstrual bleeding for premenopausal women. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness of less than 4 mm. Hysteroscopy with endometrial biopsy is also commonly used for diagnosis. Treatment for localized disease typically involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may require postoperative radiotherapy. Progestogen therapy may be used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

For individuals using the combined oral contraceptive pill for the first time, the faculty suggests a pill containing 30 mcg of estrogen.

Choice of Combined Oral Contraceptive Pill

The combined oral contraceptive pill (COCP) comes in different variations based on the amount of oestrogen and progestogen and the presentation. For first-time users, it is recommended to use a pill containing 30 mcg ethinyloestradiol with levonorgestrel/norethisterone. However, two new COCPs have been developed in recent years, namely Qlaira and Yaz, which work differently from traditional pills.

Qlaira is a combination of estradiol valerate and dienogest with a quadriphasic dosage regimen designed to provide optimal cycle control. The pill is taken every day for a 28-day cycle, with 26 pills containing estradiol +/- dienogest and two pills being inactive. The dose of estradiol is gradually reduced, and that of dienogest is increased during the cycle to give women a more natural cycle with constant oestrogen levels. However, Qlaira is more expensive than standard COCPs, and there is limited safety data to date.

On the other hand, Yaz combines 20mcg ethinylestradiol with 3mg drospirenone and has a 24/4 regime, unlike the normal 21/7 cycle. This shorter pill-free interval is better for patients with troublesome premenstrual symptoms and is more effective at preventing ovulation. Studies have shown that Yaz causes less premenstrual syndrome, and blood loss is reduced by 50-60%.

In conclusion, the choice of COCP depends on various factors such as cost, safety data, and missed pill rules. It is essential to consult a healthcare provider to determine the most suitable COCP based on individual needs and medical history.

Contraception and Pregnancy

When a woman becomes pregnant while using contraception, it is usually recommended to stop or remove the method. However, it is important to note that contraceptive hormones do not typically harm the fetus.

If an intrauterine method is in place when pregnancy is diagnosed, the woman should be informed of the potential risks of leaving it in-situ, such as second-trimester miscarriage, preterm delivery, and infection. While removal in the first trimester carries a small risk of miscarriage, it may reduce the risk of adverse outcomes. If the threads of the intrauterine contraceptive are visible or can be retrieved, it should be removed up to 12 weeks gestation, but not after this point.

Overall, it is important for women to discuss their contraceptive options with their healthcare provider and to inform them if they suspect they may be pregnant.

Urgent Referral for Unexplained Vulval Lump or Non-Responsive Ulceration

Any woman who discovers a new, unexplained lump or experiences ulceration that doesn’t respond to treatment should be referred urgently. It is important to note that the term pressure sore should be used with caution, as it may not accurately describe the condition.

If the ulcer appears to be caused by thrush, fluconazole may be considered. However, if the ulcer doesn’t arise from typical intertriginous areas and lacks satellite lesions or white discharge, a fungal infection is unlikely.

While primary syphilis can cause a solitary painless genital ulcer, it tends to resolve within four to eight weeks. Therefore, it is unlikely that this would be the first presentation of a lady with primary syphilis.

If the condition is suspected to be a pressure ulcer on the sacrum or another pressure point, a tissue viability nurse may be consulted. However, based on the given history, this seems unlikely. Referring to dermatology is not appropriate for a strongly suspected case of vulval carcinoma.

Suspected Inflammatory Breast Cancer

This patient’s medical history raises concerns for inflammatory breast cancer, a rare but easily missed subtype of breast cancer. Despite accounting for only 1-5% of cases, inflammatory breast cancer can be difficult to diagnose and is often initially misdiagnosed as mastitis. The patient’s unilateral nipple retraction, which she attributes to breastfeeding, is also a suspicious sign. Therefore, it is crucial to have a high level of suspicion and refer the patient to a breast clinic urgently.

In this scenario, advising the patient to stop breastfeeding, massage the nipple, or use a breast shield would not be appropriate. Referring routinely without considering the severity of the potential diagnosis would also not be appropriate. It is essential to prioritize the patient’s health and well-being by taking swift and appropriate action.

Pruritus vulvae can usually be attributed to an underlying cause, which can be determined through a thorough history and physical examination. The most common cause is contact dermatitis, but there are various skin conditions and infections that can also lead to vulval itching, including psoriasis, lichen simplex/planus/sclerosus, candidiasis, trichomoniasis, scabies, pubic lice, and even (pre-)malignant conditions like VIN.

Prescribing medication over the phone, video-link, or online is permitted by the GMC, as long as the healthcare provider is satisfied with the consultation and has taken into account the limitations of the communication medium and the need for examination or access to the patient’s records.

The patient has control over their information and can disclose any relevant details over the phone. Depending on the potential diagnoses, swabs and urine samples may be necessary.

Pruritus vulvae, or vaginal itching, is a common issue that affects approximately 1 in 10 women who may seek medical assistance at some point. Unlike pruritus ani, pruritus vulvae typically has an underlying cause. The most common cause is irritant contact dermatitis, which can be triggered by latex condoms or lubricants. Other potential causes include atopic dermatitis, seborrhoeic dermatitis, lichen planus, lichen sclerosus, and psoriasis, which is seen in around one-third of patients with psoriasis.

To manage pruritus vulvae, women should be advised to take showers instead of baths and clean the vulval area with an emollient such as Epaderm or Diprobase. It is recommended to clean only once a day as repeated cleaning can worsen the symptoms. Most of the underlying conditions can be treated with topical steroids. If seborrhoeic dermatitis is suspected, a combined steroid-antifungal treatment may be attempted. Overall, seeking medical advice is recommended for proper diagnosis and treatment of pruritus vulvae.

If a patient refuses a chaperone for an intimate examination and you are not comfortable performing the examination without one, it is necessary to make alternative arrangements for the patient to be examined.

As per the current guidelines of the Faculty of Sexual and Reproductive Healthcare, a speculum examination is necessary for a patient who has been experiencing problematic per vaginal bleeding with hormonal contraception for more than three months. It is crucial to examine and visualize the cervix. However, in this case, the patient has declined a male chaperone, making it a challenging situation.

While referring the patient to another service for the examination is an option, it is not appropriate for an urgent same-day admission as this is a longstanding problem. Additionally, some accident and emergency departments may not be comfortable performing speculum examinations and would refer the patient to the gynaecology department if necessary.

Referring the patient to the two-week wait clinic without examining is not appropriate as the referral may not be necessary.

Continuing with the examination without a chaperone is not advisable, especially if the clinician is uncomfortable doing so, as there is no indication of an emergency presentation.

Proceeding with the examination with a female receptionist chaperoning is not recommended as the patient has declined this and has the capacity to do so. This would be without her consent.

The most appropriate course of action would be to arrange for a suitable colleague to examine the patient the following day. As there is no indication of an acute emergency or evidence of ectopic pregnancy, deferring the examination to the following day is entirely appropriate.

GMC Guidelines on Intimate Examinations and Chaperones

The General Medical Council (GMC) has provided comprehensive guidance on how to conduct intimate examinations and the role of chaperones in the process. Intimate examinations refer to any procedure that a patient may consider intrusive or intimate, such as examinations of the genitalia, rectum, and breasts. Before performing such an examination, doctors must obtain informed consent from the patient, explaining the procedure, its purpose, and the extent of exposure required. During the examination, doctors should only speak if necessary, and patients have the right to stop the examination at any point.

Chaperones are impartial individuals who offer support to patients during intimate examinations and observe the procedure to ensure that it is conducted professionally. They should be healthcare workers who have no relation to the patient or doctor, and their full name and role should be documented in the medical records. Patients may also wish to have family members present for support, but they cannot act as chaperones as they are not impartial. Doctors should not feel pressured to perform an examination without a chaperone if they are uncomfortable doing so. In such cases, they should refer the patient to a colleague who is comfortable with the examination.

It is not mandatory to have a chaperone present during an intimate examination, and patients may refuse one. However, the offer and refusal of a chaperone should be documented in the medical records. If a patient makes any allegations against the doctor regarding the examination, the chaperone can be called upon as a witness. In cases where a patient refuses a chaperone, doctors should explain the reasons for offering one and refer the patient to another service if necessary. The GMC guidelines aim to ensure that intimate examinations are conducted with sensitivity, respect, and professionalism, while also protecting the interests of both patients and doctors.

If a woman aged 50 or above reports symptoms resembling irritable bowel syndrome within the past year, it is important to consider the possibility of ovarian cancer. While IBS is uncommon in this age group, ovarian cancer can present with similar nonspecific symptoms, and it is crucial to rule out any serious conditions.

Understanding Ovarian Cancer: Risk Factors, Symptoms, and Management

Ovarian cancer is a type of cancer that affects women, with the peak age of incidence being 60 years. It is the fifth most common malignancy in females and carries a poor prognosis due to late diagnosis. Around 90% of ovarian cancers are epithelial in origin, with 70-80% of cases being due to serous carcinomas. Interestingly, recent studies suggest that the distal end of the fallopian tube is often the site of origin of many ‘ovarian’ cancers.

There are several risk factors associated with ovarian cancer, including a family history of mutations of the BRCA1 or the BRCA2 gene, early menarche, late menopause, and nulliparity. Clinical features of ovarian cancer are notoriously vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms, early satiety, and diarrhea.

To diagnose ovarian cancer, a CA125 test is usually done initially. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 should not be used for screening for ovarian cancer in asymptomatic women. Diagnosis is difficult and usually involves diagnostic laparotomy.

Management of ovarian cancer usually involves a combination of surgery and platinum-based chemotherapy. The prognosis for ovarian cancer is poor, with 80% of women having advanced disease at presentation and the all stage 5-year survival being 46%. It is traditionally taught that infertility treatment increases the risk of ovarian cancer, as it increases the number of ovulations. However, recent evidence suggests that there is not a significant link. The combined oral contraceptive pill reduces the risk (fewer ovulations) as does having many pregnancies.

Treatment options for hypoactive sexual desire disorder in women

Hypoactive sexual desire disorder is a common issue among postmenopausal women and those who have undergone ovarian failure. While counselling and lifestyle changes may be effective in cases where the primary cause is stress or relationship issues, they may not be enough in cases where hormonal imbalances are the root cause.

If depression is the primary cause, it may need to be treated, but some antidepressants can actually worsen the problem by reducing libido. In cases where hormones are inadequate, hormone replacement therapy (HRT) may be necessary, but caution should be exercised, and an opinion from a specialist may be wise.

Androgen patches are sometimes used to treat hormone-deficient women, but their effectiveness is controversial, and they may have negative effects on the liver and cholesterol. Progestogens are not necessary for women who have had a hysterectomy and may actually make symptoms worse. Overall, treatment options for hypoactive sexual desire disorder should be tailored to the individual and their specific needs.

According to BASHH, recurrent vaginal candidiasis is characterized by experiencing four or more episodes per year. This criterion is significant as it helps determine the need for prophylactic treatment to prevent future recurrences.

Vaginal candidiasis, commonly known as ‘thrush’, is a prevalent condition that many women self-diagnose and treat. Candida albicans is responsible for 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain conditions such as diabetes mellitus, drug use (antibiotics, steroids), pregnancy, and immunosuppression (HIV) may increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, dyspareunia, dysuria, itching, vulval erythema, fissuring, and satellite lesions.

Routine high vaginal swabs are not necessary if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy. The NICE Clinical Knowledge Summaries recommends oral fluconazole 150 mg as a single dose as the first-line treatment. If oral therapy is contraindicated, a single dose of clotrimazole 500 mg intravaginal pessary may be used. If vulval symptoms are present, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments such as cream or pessaries, as oral treatments are not recommended.

Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and the diagnosis of candidiasis should be confirmed. A high vaginal swab for microscopy and culture may be necessary, and a blood glucose test should be performed to exclude diabetes. Differential diagnoses such as lichen sclerosus should also be ruled out. An induction-maintenance regime may be used, consisting of oral fluconazole every three days for three doses as induction, followed by oral fluconazole weekly for six months as maintenance.

1. Having First Child at a Young Age

Decreases Risk: Having the first child at a young age is actually associated with a lower risk of breast cancer. Women who have their first child before age 30, especially before age 20, tend to have a reduced risk compared to those who have children later in life or not at all.

Explanation: Early pregnancy reduces the total number of menstrual cycles a woman has over her lifetime, reducing exposure to estrogen and progesterone, which are associated with breast cancer development.

2. Early Menopause

Decreases Risk: Experiencing menopause at an earlier age is associated with a lower risk of breast cancer.

Explanation: Early menopause means fewer menstrual cycles and reduced lifetime exposure to estrogen, which is linked to the development of breast cancer.

3. Multiparity (Having Multiple Pregnancies)

Decreases Risk: Having multiple pregnancies generally reduces the risk of breast cancer.

Explanation: Similar to having a first child at a young age, multiple pregnancies lower the total number of menstrual cycles and thereby reduce lifetime hormone exposure, decreasing breast cancer risk.

4. A Mother Who Has Breast-Fed Her Baby

Decreases Risk: Breastfeeding is associated with a lower risk of breast cancer.

Explanation: Breastfeeding reduces the number of menstrual cycles, which reduces hormone exposure. Additionally, lactation may lead to changes in breast cells that make them more resistant to cancer.

5. Hormone Replacement Therapy (HRT)

Increases Risk: Hormone replacement therapy, particularly combined estrogen-progesterone therapy, is associated with an increased risk of breast cancer.

Explanation: HRT increases the exposure to estrogen and progesterone, which can promote the development and growth of hormone-sensitive breast cancer cells. The risk is higher with longer duration of use and decreases after stopping the therapy.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimens. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Recognizing Inflammatory Breast Cancer

Most GPs and patients are familiar with the presentation of a breast lump, but inflammatory breast cancer can present in a more unusual way, making a swift diagnosis difficult. However, simply considering the possibility of this rare form of breast cancer can help pick out relevant information in the patient’s history and examination. Inflammatory breast cancer is not common, accounting for only 1-4% of all breast cancers, which can lead to delayed diagnosis in primary care. Patients with a personal or family history of breast cancer, symptoms of non-lactational mastitis that do not respond to antibiotics, palpable lymphadenopathy, involvement of more than 1/3 of the breast, and an absence of fever should be considered at high risk for inflammatory breast cancer.

It is important for GPs to ask about family history of breast cancer and check and record temperature when seeing patients with mastitis. Blindly prescribing another course of antibiotics, especially when the patient doesn’t have a fever or symptoms of infection, may delay diagnosis. Suggesting milk expression would be reasonable for lactational mastitis, but not for a patient who stopped breastfeeding six months ago. Attempting to aspirate would not be advisable for a generalist in a primary care setting, even if an abscess were suspected. Referring the patient to the Emergency department for assessment by a breast surgeon would be a wiser strategy.

The patient has breast engorgement and should be advised to feed the infant with no restrictions on frequency and length of feeds. Analgesia with opioids is not recommended, and support measures such as breast massage and cold gel packs are the mainstay of treatment. Mastitis is a differential diagnosis, but hospital admission is not necessary unless there are signs of sepsis or rapidly progressing infection. Other causes of breast pain or discomfort in breastfeeding women include a full breast, a blocked duct, mastitis, or a breast abscess. Deep breast pain may also be caused by ductal infection, spasm of the ducts, persistent reaction to nerve trauma, or prolactin-induced mastalgia.

Breastfeeding Problems and Management

Breastfeeding can come with its own set of challenges, but most of them can be managed with proper care and attention. Some common issues include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These problems can be addressed by seeking advice on positioning, breast massage, and using appropriate creams and suspensions.

Mastitis is a more serious condition that affects around 1 in 10 breastfeeding women. It is important to seek treatment if symptoms persist or worsen, including systemic illness, nipple fissures, or infection. The first-line antibiotic is flucloxacillin, and breastfeeding or expressing should continue during treatment. If left untreated, mastitis can lead to a breast abscess, which requires incision and drainage.

Breast engorgement is another common issue that can cause pain and discomfort. It usually occurs in the first few days after birth and can affect both breasts. Hand expression of milk can help relieve the discomfort of engorgement, and complications can be avoided by addressing the issue promptly.

Raynaud’s disease of the nipple is a less common but still significant problem that can cause pain and blanching of the nipple. Treatment options include minimizing exposure to cold, using heat packs, avoiding caffeine and smoking, and considering oral nifedipine.

Concerns about poor infant weight gain can also arise, prompting consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight until weight gain is satisfactory is also recommended. With proper management and support, most breastfeeding problems can be overcome, allowing for a successful and rewarding breastfeeding experience.

A pH level greater than 4.5 is linked to Trichomonas vaginalis and bacterial vaginosis.

Comparison of Bacterial Vaginosis and Trichomonas Vaginalis

Bacterial vaginosis and Trichomonas vaginalis are two common sexually transmitted infections that affect women. Bacterial vaginosis is caused by an overgrowth of bacteria in the vagina, while Trichomonas vaginalis is caused by a protozoan parasite. Both infections can cause vaginal discharge and vulvovaginitis, but Trichomonas vaginalis may also cause urethritis in men.

The vaginal discharge in bacterial vaginosis is typically thin and grayish-white, with a fishy odor. The pH of the vagina is usually higher than 4.5. In contrast, the discharge in Trichomonas vaginalis is offensive, yellow/green, and frothy. The cervix may also appear like a strawberry. The pH of the vagina is also higher than 4.5.

To diagnose bacterial vaginosis, a doctor may perform a pelvic exam and take a sample of the vaginal discharge for testing. The presence of clue cells, which are vaginal cells covered in bacteria, is a hallmark of bacterial vaginosis. On the other hand, Trichomonas vaginalis can be diagnosed by examining a wet mount under a microscope. The motile trophozoites of the parasite can be seen in the sample.

Both bacterial vaginosis and Trichomonas vaginalis can be treated with antibiotics. Metronidazole is the drug of choice for both infections. For bacterial vaginosis, a course of oral metronidazole for 5-7 days is recommended. For Trichomonas vaginalis, a one-off dose of 2g metronidazole may also be used. It is important to complete the full course of antibiotics to ensure that the infection is fully treated.

Urgent Action Required for Haemodynamically Unstable Patient

The most appropriate course of action in this case is to call 999 and request an ambulance. This patient may have an ectopic pregnancy or may be miscarrying, and is therefore unstable and requires immediate resuscitation and transfer to hospital. While waiting for the ambulance, an attempt at IV cannulation and fluid resuscitation should be made.

Arranging an assessment at the EPAU within 24 hours is inappropriate, as the patient is haemodynamically unstable and requires urgent admission via ambulance. Conducting a pelvic exam is not appropriate as this patient is haemodynamically unstable and has abdominal tenderness. Similarly, conducting a urine pregnancy test or taking blood for a serum βHCG would only cause unnecessary delay.

It is crucial to prioritize the patient’s immediate medical needs and take urgent action to ensure their safety and well-being.

Suspected Endometrial Cancer in postmenopausal Woman with Abnormal Bleeding

According to the 2015 NICE guidelines, women aged 55 and over with postmenopausal bleeding should be referred for suspected cancer pathway referral within two weeks. This includes women who experience unexplained vaginal bleeding more than 12 months after menstruation has stopped due to menopause.

In this case, the patient’s periods stopped 18 months ago, making her postmenopausal. Her recent bleeding episode, along with her nulliparity, obesity, menopause after 52, and family history of hereditary nonpolyposis colon cancer, all increase her risk for endometrial cancer. Although bleeding can occur when using HRT, the patient began bleeding six months after initiating HRT, and the bleeding persisted four weeks after stopping HRT, making it less likely that the medication is the cause.

Re-initiating HRT would be contraindicated until endometrial cancer is ruled out. While the patient has not experienced post-coital bleeding and has a normal-looking cervix with normal smear results, referral for colposcopy would not be the most appropriate next step. Inserting a Mirena coil may be useful in managing troublesome bleeding associated with HRT, but it would not be appropriate until the patient is investigated for endometrial cancer.